Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

243 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Respiratory Syncytial Virus Prefusion F Protein Vaccine Is Efficacious in Older Adults With Underlying Medical Conditions.
Feldman RG, Antonelli-Incalzi R, Steenackers K, Lee DG, Papi A, Ison MG, Fissette L, David MP, Maréchal C, Van der Wielen M, Kostanyan L, Hulstrøm V; AReSVi-006 Study Group. Feldman RG, et al. Among authors: david mp. Clin Infect Dis. 2024 Jan 25;78(1):202-209. doi: 10.1093/cid/ciad471. Clin Infect Dis. 2024. PMID: 37698366 Free PMC article.
The RSVPreF3-AS01 vaccine elicits broad neutralization of contemporary and antigenically distant respiratory syncytial virus strains.
Sacconnay L, De Smedt J, Rocha-Perugini V, Ong E, Mascolo R, Atas A, Vanden Abeele C, de Heusch M, De Schrevel N, David MP, Bouzya B, Stobbelaar K, Vanloubbeeck Y, Delputte PL, Mallett CP, Dezutter N, Warter L. Sacconnay L, et al. Among authors: david mp. Sci Transl Med. 2023 Aug 23;15(710):eadg6050. doi: 10.1126/scitranslmed.adg6050. Epub 2023 Aug 23. Sci Transl Med. 2023. PMID: 37611082
Leveraging Influenza Virus Surveillance From 2012 to 2015 to Characterize the Burden of Respiratory Syncytial Virus Disease in Canadian Adults ≥50 Years of Age Hospitalized With Acute Respiratory Illness.
ElSherif M, Andrew MK, Ye L, Ambrose A, Boivin G, Bowie W, David MP, Gruselle O, Halperin SA, Hatchette TF, Johnstone J, Katz K, Langley JM, Loeb M, MacKinnon-Cameron D, McCarthy A, McElhaney JE, McGeer A, Poirier A, Pirçon JY, Powis J, Richardson D, Semret M, Smith S, Smyth D, Trottier S, Valiquette L, Webster D, McNeil SA, LeBlanc JJ; Serious Outcomes Surveillance (SOS) Network of the Canadian Immunization Research Network (CIRN) and the Toronto Invasive Bacterial Diseases Network (TIBDN). ElSherif M, et al. Among authors: david mp. Open Forum Infect Dis. 2023 Jun 13;10(7):ofad315. doi: 10.1093/ofid/ofad315. eCollection 2023 Jul. Open Forum Infect Dis. 2023. PMID: 37441353 Free PMC article.
Efficacy and safety of respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over 2 RSV seasons.
Ison MG, Papi A, Athan E, Feldman RG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Verheust C, Dezutter N, Gruselle O, Fissette L, David MP, Kostanyan L, Hulstrøm V, Olivier A, Van der Wielen M, Descamps D; AReSVi-006 study group. Ison MG, et al. Among authors: david mp. Clin Infect Dis. 2024 Jan 22:ciae010. doi: 10.1093/cid/ciae010. Online ahead of print. Clin Infect Dis. 2024. PMID: 38253338
Current clinical practices and challenges in molecular testing: a GOAL Consortium Hematopathology Working Group report.
Lee TD, Aisner DL, David MP, Eno CC, Gagan J, Gocke CD, Guseva NV, Haley L, Jajosky AN, Jones D, Mansukhani MM, Mroz P, Murray SS, Newsom KJ, Paulson V, Roy S, Rushton C, Segal JP, Senaratne TN, Siddon AJ, Starostik P, Van Ziffle JAG, Wu D, Xian RR, Yohe S, Kim AS. Lee TD, et al. Among authors: david mp. Blood Adv. 2023 Aug 22;7(16):4599-4607. doi: 10.1182/bloodadvances.2023010149. Blood Adv. 2023. PMID: 37236162 Free PMC article.
Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults.
Papi A, Ison MG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Campora L, Dezutter N, de Schrevel N, Fissette L, David MP, Van der Wielen M, Kostanyan L, Hulstrøm V; AReSVi-006 Study Group. Papi A, et al. Among authors: david mp. N Engl J Med. 2023 Feb 16;388(7):595-608. doi: 10.1056/NEJMoa2209604. N Engl J Med. 2023. PMID: 36791160 Clinical Trial.
Safety and immunogenicity of a respiratory syncytial virus prefusion F protein (RSVPreF3) candidate vaccine in older Japanese adults: A phase I, randomized, observer-blind clinical trial.
Kotb S, Haranaka M, Folschweiller N, Nakanwagi P, Verheust C, De Schrevel N, David MP, Mesaros N, Hulstrøm V. Kotb S, et al. Among authors: david mp. Respir Investig. 2023 Mar;61(2):261-269. doi: 10.1016/j.resinv.2022.11.003. Epub 2023 Jan 12. Respir Investig. 2023. PMID: 36641341 Free article. Clinical Trial.
Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial.
Leroux-Roels I, Davis MG, Steenackers K, Essink B, Vandermeulen C, Fogarty C, Andrews CP, Kerwin E, David MP, Fissette L, Vanden Abeele C, Collete D, de Heusch M, Salaun B, De Schrevel N, Koch J, Verheust C, Dezutter N, Struyf F, Mesaros N, Tica J, Hulstrøm V. Leroux-Roels I, et al. Among authors: david mp. J Infect Dis. 2023 Mar 28;227(6):761-772. doi: 10.1093/infdis/jiac327. J Infect Dis. 2023. PMID: 35904987 Free PMC article. Clinical Trial.
243 results